ÜROTELYAL MESANE KANSERİ NEDENİYLE RADİKAL SİSTEKTOMİ YAPILAN 14 KADIN HASTANIN ONKOLOJİK SONUÇLARI VE SAĞKALIM VERİLERİNİN DEĞERLENDİRİLMESİ

Giriş: Mesane kanseri nedeniyle radikal sistektomi yapılan kadın hastaların onkolojik sonuçlarını ve sağkalım verilerini değerlendirmek Gereç ve Yöntem: Kliniğimizde mesane kanseri nedeniyle Ocak 2006-Kasım 2016 tarihleri arasında radikal sistektomi operasyonu yapılan hastaların verileri retrospektif olarak incelendi. Bu hastalar arasından 14 kadın hasta çalışmaya dahil edildi. Bulgular: Mesane kanseri nedeniyle radikal sistektomi yapılan 178 hasta vardı. Bu hastalardan 156(%91.7) sı erkek, 14 (%8.3) ü kadındı. Kadın hastaların yaş ortalaması 63.2(±10.1) idi. Kadın hastaların preoperatif değerlendirmesinde 13 hastada organa sınırlı hastalık varken 1 hasta lokal ileri evredeydi. Üriner diversiyon çeşidi olarak 6 hastaya ileal conduit, 8 hastaya ise üreterokutanostomi yapıldı. Kadın hastalarda genel sağkalım 45.4±12.6 ay, kansere özgü sağkalım ise 49.2±13.2 ay olarak bulundu. Sonuç: Kadınlarda kasa invaze mesane kanseri, organa sınırlı evrede tanı konulup tedavi edildiği zaman etkin onkolojik kontrol ve sağkalım sonuçları elde edilebilir.

EVALUATION OF ONCOLOGIC RESULTS AND SURVIVAL DATA OF 14 FEMALE PATIENTS WHO UNDERWENT RADICAL CYSTECTOMY DUE TO UROTHELIAL BLADDER CANCER

Introduction:To evaluate the oncological outcomes and survival data of female patients who underwent radical cystectomy due to bladder cancer. Materials and methods:The data of patients who underwent radical cystectomy operation due to bladder cancer were reviewed retrospectively between January 2006 and November 2016 in our clinic,. Of these patients, 14 female patients were included in this study. Results:There were 178 patients who underwent radical cystectomy due to bladder cancer. Of these patients, 156 (91.7%) were male and 14 (8.3%) were female. The mean age of the female patients was 63.2 (± 10.1). In preoperative evaluation of female patients, 13 patients had organ-limited disease while 1 patient had local advanced disease. In female patients; overall survival was 45.4 ± 12.6 months while cancer-specific survival was 49.2 ± 13.2 months. Conclusion:In women, effective oncologic control and survival results can be obtained when muscle invasive bladder cancer is diagnosed and treated at organ-confined stage.

___

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61(2):69–90.

Rogers CG, Palapattu GS, Shariat SF, Karakiewicz PI, Bastian PJ, Lotan Y, et al. Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma of the bladder compared to transitional cell carcinoma of the bladder. J Urol 2006;175(6):2048-53.

Ploeg M, Aben KK, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J Urol 2009;27:289-93.

Manunta A, Vincendeau S, Kiriakou G, Lobel B, Guille F. Nontransitional cell bladder carcinomas. BJU Int 2005;95(4):497- 502.

Ahmed HU, Arya M, Patel HR. Bladder carcinoma: understanding advanced and metastatic disease with potential molecular therapeutic targets. Expert Rev Anticancer Ther 2005;5(6):1011-22.

Shariat SF, Sfakianos JP, Droller MJ, Karakiewicz PI, Meryn S, Bochner BH. The effect of age and gender on bladder cancer: a critical review of the literature. BJU Int 2010;105(3):300–8.

Horstmann M, Witthuhn R, Falk M, Stenzl A. Gender-specific differences in bladder cancer: a retrospective analysis. Gend Med 2008;5(4):385–94.

Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56(2): 106-30.

Hartge P, Harvey EB, Linehan WM, Silverman DT, Sullivan JW, Hoover RN, et al. Unexplained excess risk of bladder cancer in men. J Natl Cancer Inst 1990; 82(20): 1636-40.

Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999; 80(6): 827-41.

Ruiz Cerdá JL, Alfonso Gil R, Domenech Ferrando E, Pascual Bueno J, Vera Donoso CD, Martínez Jabaloyas J, et al. The evolution over time (1960-1990) of mortality and the ratio of males in bladder cancer in Spain. Actas Urol Esp 1995; 19(3): 196-202.

van der Poel HG, Mungan NA, Witjes JA. Bladder cancer in women. Int Urogynecol J Pelvic Floor Dysfunct 1999; 10(3): 207-1.

Madersbacher S, Hochreiter W, Burkhard F, Thalmann GN, Danuser H, Markwalder R, et al. Radical cystectomy for bladder cancer today-a homogeneous series without neoadjuvant therapy. J Clin Oncol 2003; 21(4): 690-6.

Kluth LA, Rieken M, Xylinas E, Kent M, Rink M, Rouprêt M, et al. Gender spesific differences in clinicopathologic outcomes following radical cystectomy: an international multi-institutional study of more than 8000 patients. Eur Urol. 2014; 66(5): 913-9.

Noon AP, Albertsen PC, Thomas F, Rosario DJ, Catto JW. Competing mortality in patients diagnosed with bladder cancer: evidence of undertreatment in the elderly and female patients. Br J Cancer 2013; 108(7): 1534–40.

Lyratzopoulos G, Abel GA, McPhail S, Neal RD, Rubin GP. Gender inequalities in the promptness of diagnosis of bladder and renal cancer after symptomatic presentation: evidence from secondary analysis of an English primary care audit survey. BMJ Open 2013; 3(6): e002861.

Shen SS, Smith CL, Hsieh JT, Yu J, Kim IY, Jian W, et al. Expression of estrogen receptorsalpha and -beta in bladder cancer cell lines and human bladder tumor tissue. Cancer 2006; 106(12): 2610–6.

Saez S, Martin PM. Evidence of estrogen receptors in the trigone area of human urinary bladder. J Steroid Biochem 1981; 15: 317–20.

Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Kosary CL, et al. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). Bethesda: National Cancer Institute: 2012.

Pichler R, Fritz J, Heidegger I, Oberaigner W, Horninger W, Hochleitner M. Gender-related outcome in bladder cancer patients undergoing radical cystectomy. J Cancer. 2017; 8(17): 3567-74.

___